Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press September 7, 2010, 4:21PM ET

Drug company Zogenix plans initial public offering

Specialty pharmaceutical company Zogenix Inc. has again filed for an initial public offering of common stock, more than two years after it first announced plans to go public.

The San Diego company looks to raise up to $90 million, according to a registration statement filed with the Securities and Exchange Commission. The company said the estimated value of the offering isn't final and was calculated to determined the registration fee.

The number of shares to be offered and the price range for the offering also have not been determined.

Zogenix specializes in developing products for the treatment of central nervous system disorders and pain. It launched the migraine treatment Sumavel DosePro in January. It also has ZX002, a potential treatment for moderate-to-severe chronic pain, in late-stage clinical testing.

It plans to use net proceeds from the offering to fund the ongoing commercialization of Sumavel DosePro and the development of ZX002, among other uses.

The company proposes the ticker symbol 'ZGNX.'

Zogenix said it is in the early stages of commercialization and has incurred big losses since its inception. Its net loss for the first six months of 2010 was $49.3 million, with only $7.6 million in revenue.

The company filed plans for an IPO in 2008 and then withdrew them, said Scott Sweet, senior managing partner at IPOBoutique.

He said they may have a tough time drumming up interest. Regulatory approval delays and a lack of new blockbuster drugs have made investors reluctant to tie up their money in biotech stocks.

Biomedical or biotech IPOs, in particular, have struggled this year.

"Many have been postponed," Sweet said. "Many have had to cut their price in half and still have been postponed."

BW Mall - Sponsored Links

Buy a link now!